Region Joenkoepings Laen

Running trials

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· Source

• Recruiting

  Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment

  2025-524022-18-00· Phase 2· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Source

• Recruiting

  A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil

  NCT07199946· Phase 1/2· Source

• Recruiting

  A clinical phase IV trial to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.

  2024-511182-10-01· Phase 4· Source

• Recruiting

  Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)

  2023-506998-35-00· Phase 3· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Recruiting

  Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

  NCT06488482· Phase 3· Source

• Recruiting

  Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial (DISRITUX)

  2023-508398-10-00· Phase 4· Source

• Active, not recruiting

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· Phase 3· Source

• Active, not recruiting

  Ixekizumab Diabetes Intervention Trial (I-DIT)

  NCT04589325· Phase 2· Source

• Recruiting

  Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

  NCT05284552· Phase 2· Source

• Recruiting

  Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

  NCT04910802· Phase 4· Source

• Active, not recruiting

  A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· Phase 3· Source

• Active, not recruiting

  Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial)

  2023-504945-30-00· Phase 3· Source

• Active, not recruiting

  NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

  NCT04335669· Phase 3· Source

• Recruiting

  ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

  NCT03903835· Phase 3· Source

• Recruiting

  Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

  NCT02901184· Phase 3· Source

• Active, not recruiting

  Adjuvant Low Dose Aspirin in Colorectal Cancer

  NCT02647099· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• ANCA-associated vasculitis1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Glioblastoma1 recruiting
• Heart failure1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Source

• Active, not recruiting

  OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure

  NCT04789239· Phase 2· Source

• Active, not recruiting

  A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast cancer

  NCT03975647· Phase 3· Source

• Completed

  SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

  NCT03982381· Phase 4· Source

• Completed

  Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856· Phase 3· Source

• Active, not recruiting

  Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

  NCT03869892· Phase 3· Source